Proteomic identification of prognostic tumour biomarkers, using chemotherapy-induced cancer-associated fibroblasts by Peiris-Pagès, M et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
Unlike normal healthy fibroblasts, aged or senescent 
fibroblasts are pro-tumorigenic [1]. Cellular damage, 
which is widely considered to be the general cause of 
aging, occasionally may provide cells with abnormal 
advantages that can eventually give rise to cancer. Thus, 
cancer and aging are two different faces of the same 
underlying process: the accumulation of cellular 
damage in cells and tissues over the years, which 
eventually become senescent.  Indeed,  accumulation  of 
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senescent cells has been detected after examination of 
aged tissues, and it contributes to tissue degeneration 
during aging [1]. Whether senescence of the stroma is 
sufficient to initiate tumorigenesis still remains unclear.  
However, senescent cells can have profound effects on 
the surrounding microenvironment, through the 
expression and secretion of a range of pro-inflammatory 
factors, which is known as the senescence-associated 
secretory phenotype (SASP). The onset of SASP may 
help explain the increased tumor incidence observed in 
aged individuals [2].  
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Abstract: Cancer  cells  grow  in  highly  complex  stromal  microenvironments,  which  through  metabolic  remodelling,
catabolism, autophagy and  inflammation nurture  them and are able  to  facilitate metastasis and  resistance  to  therapy.
However,  these  changes  in  the metabolic  profile  of  stromal  cancer‐associated  fibroblasts  and  their  impact  on  cancer
initiation, progression and metastasis are not well‐known. This  is  the  first study  to provide a comprehensive proteomic
portrait of the azathioprine and taxol‐induced catabolic state on human stromal fibroblasts, which comprises changes  in
the  expression  of  metabolic  enzymes,  myofibroblastic  differentiation  markers,  antioxidants,  proteins  involved  in
autophagy, senescence, vesicle trafficking and protein degradation, and  inducers of  inflammation. Interestingly, many of
these features are major contributors to the aging process. A catabolic stroma signature, generated with proteins found
differentially up‐regulated  in taxol‐treated  fibroblasts, strikingly correlates with recurrence, metastasis and poor patient
survival in several solid malignancies. We therefore suggest the inhibition of the catabolic state in healthy cells as a novel
approach to improve current chemotherapy efficacies and possibly avoid future carcinogenic processes. 
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The tumour stroma comprises the majority of the 
neoplastic mass and is mainly composed of fibroblasts 
[3]. Nevertheless, our comprehension of the tumour 
microenvironment is rather limited in comparison with 
that of cancer cells. The emergence of a reactive 
microenvironment via metabolic stress and 
inflammation fuels cancer cells, enables tumour growth 
and invasion, and leads to treatment failure [3-10]. 
However, the mechanisms by which the metabolic 
remodelling of cancer-associated stromal fibroblasts 
(CAFs) regulates the evolution of malignancy or even 
may control the susceptibility of incompletely 
transformed cells to become fully malignant are not 
fully understood.  
 
We have previously established that exposure to anti-
cancer agents independently drives metabolic stress and 
catabolism, autophagy, senescence, myofibroblastic 
differentiation and production of the pro-inflammatory 
cytokine Interleukin 6 (IL6) in human stromal 
fibroblasts in vitro (Figure 1) [11]. Thus, according to 
our model, chemotherapy promotes the same effects in 
stromal fibroblasts as their interaction with cancer cells, 
the so-called catabolic tumour stroma phenotype, which 
creates an energy-rich, pro-inflammatory niche ideal for 
cancer development and possibly initiation. 
 
Despite the significant number of markers and secreted 
proteins already related to CAFs, there is little evidence 
of the contribution of chemotherapy-induced CAF 
transformation to metastasis or the growth of a second 
primary tumour after therapy. Indeed, only one report 
links secretion of factors associated with inflammation 
and cancer progression in therapy-damaged senescent 
fibroblasts with de novo tumorigenesis [12]. Thus, 
novel biomarkers are required to improve the prediction 
of recurrence, metastasis and, in particular, the 
prediction of therapy-related carcinogenesis. So far, 
there is one study investigating transcriptomic changes 
in stromal fibroblasts upon chemotherapeutic treatment, 
but none investigating phenotypic changes by 
proteomics [11]. Azathioprine and taxol (paclitaxel) are 
drugs widely used in chemotherapy for a variety of 
cancers and in particular taxol is used as the first-line 
chemotherapeutic agent for ovarian cancer [13-15]. In 
this study, we describe a strategy based on a label-free 
quantitative proteomic profiling of fibroblasts obtained 
after treatment with azathioprine or taxol, which allows 
us to measure numerous markers of the CAF phenotype. 
Likewise, the data presented here attempt to identify 
novel biomarkers of the catabolic remodelling in human 
stromal fibroblasts that are associated with 
chemoresistance, metastasis and second primary 
tumours by reporting their impact on cancer survival.  
The expression of several over-expressed proteins found 
in taxol-treated fibroblasts that are involved in 
metabolism, antioxidant response, autophagy, vesicle 
trafficking, protein degradation and myofibroblastic 
transformation correlate with poor prognosis in 
chemotherapy-treated breast, lung, gastric and ovarian 
cancer patients. We conclude that a strategy that targets 
constituents of the tumour microenvironment in 
combination with conventional chemotherapy may help 
improving treatment efficacy and avoiding the growth 
of future malignancies. 
 
RESULTS  
 
To identify differentially regulated proteins upon 
chemotherapeutic treatment, hTERT-BJ1 fibroblasts 
were exposed for 48 h to either vehicle or sub-lethal 
concentrations of azathioprine (100 µM) or taxol (100 
nM) (Figure S1), and cell lysates were subject to label-
free quantitative proteomics. Following protein 
digestion with trypsin, peptide fractions were processed 
on an LTQ-Orbitrap XL mass spectrometer. The 
experimental workflow used for the present study is 
depicted in Figure 2. Those peptides identified were 
further analyzed to find proteomic changes between 
chemotherapy-treated and vehicle-treated fibroblasts. 
To define differential regulation, those identified 
proteins that showed a fold change difference of 1.15 or 
higher, and p values of <0.05 (ANOVA) compared to 
vehicle were considered. In the azathioprine-treated 
fibroblasts, 1640 proteins were identified as 
differentially expressed, from which 779 were up-
regulated and 861, down-regulated. In the taxol 
treatments, 2967 proteins were found as differentially 
expressed compared to vehicle, from which 1624 were 
up-regulated and 1343, down-regulated (Figure 3A).  
 
To obtain additional functional insights into pathways 
that are differentially regulated in stromal fibroblasts 
upon treatment, bioinformatics analyses of our 
proteomics datasets were conducted. All differentially 
expressed proteins were analysed using Ingenuity 
Pathway Analysis (IPA) to seek altered canonical 
pathways and toxicity functions. IPA was able to 
analyse 633 proteins out of 1640 in the azathioprine-
treated fibroblasts, and 841 out of 2967 proteins in the 
taxol-treated fibroblasts. We further examined the 
subcellular distribution and the nature of these 
differentially regulated proteins in azathioprine and 
taxol-treated fibroblasts. Over 80% of all proteins 
analyzed were intracellular, in particular cytoplasmic 
proteins (Figure 3B). Likewise, the largest portion of 
classified proteins, accounting for one fourth of all 
analysed proteins, were enzymes, over 8% of all 
proteins were transporter proteins, and over 7% were 
transcription regulators (Figure 3C). Finally, a  comparison 
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analysis revealed that 352 proteins were differentially 
regulated in both treatment conditions compared to 
vehicle (Figure 3D). 
 
Cellular pathways affected by chemotherapy in 
stromal fibroblasts 
 
1. Metabolism 
 
One of the major contributors to the aging process is 
mitochondrial dysfunction, which involves a decrease in 
the oxidative phosphorylation efficacy and an increase 
in the electron leakage resulting in reduced ATP 
generation [17]. Similarly, one of the hallmarks of the 
catabolic tumour stroma is the induction of metabolic 
stress that favours glycolysis to the detriment of 
mitochondrial metabolism. We have showed in a 
previous study that several chemotherapeutic agents, 
including azathioprine and taxol were able to stimulate 
stromal fibroblasts to consume more glucose and 
produce more lactate, which was released via enhanced 
MCT4 expression, hence increasing extracellular 
acidification (Figure 1). The cellular ATP content was 
also minor upon treatment suggesting a decrease in 
mitochondrial respiration [11].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Workflow  for  the comparative proteome analysis
of hTERT‐BJ1 fibroblasts treated with azathioprine, taxol or
vehicle. Protein  lysates were obtained  from hTERT‐BJ1  fibroblasts 
after  48  h  treatment with  azathioprine,  taxol  or  vehicle.  Peptides
obtained after trypsin digestion were analysed via LC‐MS/MS on an 
LTQ‐Orbitrap  XL  mass  spectrometer.  Label‐free  quantitative
proteomics  was  used  to  detect  changes  in  protein  abundances
across  vehicle‐treated  and  drug‐treated  fibroblast  extracts.  The
proteomics data sets were further analysed using Ingenuity Pathway
Analysis and a cancer survival analysis tool (kmplot.com). 
Figure  1.  Chemotherapy  induces  the 
catabolic  tumour  stroma  phenotype.  ROS 
production  and  DNA  damage  induced  by 
chemotherapy  generate  oxidative  stress  to 
stromal cells, which  in turn brings about several 
changes  in  them  such  as  differentiation  into 
CAFs, activation of HIF1α, NFkB, TGFβ, STAT3 or 
JNK/AP1  signalling  pathways,  switch  to  aerobic 
glycolysis  and  loss  of  functional  mitochondria, 
acquisition  of  an  autophagic  and  senescent 
phenotype,  and  release  of  pro‐inflammatory 
cytokines.  Thus,  these  stromal  fibroblasts 
acquire the catabolic tumour stroma phenotype. 
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Figure 3. Overview of proteins and pathways  identified as differentially  regulated  in  the  lysates of azathioprine‐
treated and taxol‐treated fibroblasts relative to vehicle by Ingenuity Pathway Analysis. (A) Volcano plot representation
of protein abundance changes in hTERT‐BJ1 fibroblasts upon treatment with azathioprine and taxol compared to vehicle treatment.
A total of 1640 differentially regulated proteins with fold changes ≥ 1.15 and p values < 0.05 were identified in azathioprine‐treated
fibroblasts,  and  2967  differentially  regulated  proteins  in  taxol‐treated  fibroblasts.  X  axis  represents  log2(fold  change).  Y  axis
represents ‐log(p value). Non‐significantly regulated proteins are shown in grey, in green, significantly down‐regulated proteins and
in red, significantly up‐regulated proteins. (B) Subcellular  localization of differentially regulated proteins  identified  in azathioprine
and taxol treatments compared to vehicle treatment. (C) Classification of differentially regulated proteins identified in azathioprine
and taxol treatments by type. Cellular enzymes account for 22.04% and 25.40% of total differentially regulated proteins identified
in  azathioprine  treatment  and  taxol  treatment,  respectively.  (D)  Overlap  of  differentially  regulated  proteins  identified  in
azathioprine and taxol treatments compared to vehicle treatment. Of all proteins identified by quantitative proteomics, 352 were
proteins  the  expression  of which was  found  altered  in  both  treatments  compared  to  vehicle.  (E)  Canonical  pathways  and  (F)
upstream regulators identified or predicted as altered in both treatment conditions compared to vehicle. A positive z score is indicated
in orange and points towards an activation of the pathway, and a negative z score, in blue, indicates an inhibition of the pathway. 
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To validate that chemotherapy-induced glycolytic 
phenotype and to identify other cellular metabolic 
pathways potentially altered by chemotherapy, we 
searched the proteomic data for  changes  in  the  expres- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
sion of metabolic enzymes. Of all differentially 
regulated proteins, 22.04% and 25.40% were actually 
enzymes in azathioprine-treated and taxol-treated 
fibroblasts, respectively (Figure 3C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Changes in the expression of enzymes involved in glucose metabolism after treatment with 
azathioprine and taxol for 48 h as measured by quantitative proteomics. 
 
GLYCOLYSIS Azathioprine Taxol
Solute carrier family 2 (facilitated glucose transporter), member 1 
(GLUT1) SLC2A1 ↑ 1.18 
 
Hexokinase 
HK1  ↑ 1.43 
HK2 ↑ 2.46  
Glucose-6-phosphate isomerase  GPI  ↓ 1.27 
6-phosphofructokinase type C PFKP  ↑ 1.56 
Fructose-bisphosphate aldolase A ALDOA ↑ 2.10 ↓ 11.58 
Glyceraldehyde-3-phosphate dehydrogenase GAPDH ↑ 1.90 ↑ 1.89 
Triosephosphate isomerase 1 TPI1   ↑ 1.33 
Phosphoglycerate kinase 1 PGK1  ↓ 1.58 
Phosphoglycerate mutase 
PGAM1  ↓ 1.38 
PGAM4 ↓ 1.45  
Enolase 1 ENO1 ↓ 1.37  
Pyruvate kinase  PKM  ↑ 1.65 
POST-GLYCOLYSIS PROCESSES Azathioprine Taxol
L-lactate dehydrogenase A chain  LDHA ↓ 1.47 ↓ 1.46 
Monocarboxylate transporter 4 (MCT4) SLC16A3  ↑ 2.21 
Pyruvate dehydrogenase  PDHB ↓ 1.20 ↓ 1.40 
GLUCONEOGENESIS Azathioprine Taxol
Glucose-6-phosphate isomerase  GPI ↓ 1.27 
 Aldolase A, fructose-bisphosphate ALDOA ↑ 2.10 ↓ 11.57 
 Glyceraldehyde-3-phosphate dehydrogenase GAPDH ↑ 1.90 ↑ 1.89 
 Phosphoglycerate kinase 1 PGK1 ↓ 1.58 
 Phosphoglycerate mutase  
PGAM1 ↓ 1.38 
PGAM4 ↓ 1.45 
 Enolase 1 ENO1 ↓ 1.37 
 Malate dehydrogenase 
MDH1 ↓ 1.80 
MDH2 ↓ 1.23 
 Malic enzyme 2, NAD(+)-dependent, mitochondrial ME2 ↓ 1.62 
PENTOSE PHOSPHATE PATHWAY  Azathioprine Taxol
Glucose-6-phosphate dehydrogenase 
G6PD ↓ 2.03 ↑ 2.69 
H6PD ↑ 1.46 
6-phosphogluconolactonase PGLS ↑ 1.54 
Phosphogluconate dehydrogenase PGD ↓ 1.57 
Transketolase TKT ↓ 1.88 
Transaldolase TALDO ↑ 2.13 
HEXOSAMINE BIOSYNTHESIS PATHWAY Azathioprine Taxol
Glutamine-fructose-6-phosphate transaminase 1 GFPT1 ↑ 1.36 
Glucosamine-6-phosphate deaminase 1 GNPDA1 ↑ 2.46 
Chemotherapy  increased  the expression of  several enzymes  involved  in glycolysis, pentose phosphate pathway, and 
hexosamine biosynthesis. Enzymes that show amplified expression after treatment are shown in red, and enzymes that 
are  decreased  are  shown  in  green.  Number  indicates  the  fold  increase  or  fold  decrease  in  protein  expression  in 
chemotherapy‐treated versus vehicle‐treated hTERT‐BJ1 fibroblasts.
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The expression of most glycolytic enzymes was 
significantly altered (Table 1). Interestingly, most of the 
glycolytic enzymes that were found to be up-regulated 
are enzymes that perform an irreversible reaction in the 
glycolytic pathway and all down-regulated enzymes are 
reversible  enzymes,  able  to  perform  the  opposite  re- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
action, hence also involved in gluconeogenesis. 
Curiously, LDHA, the enzyme involved in transforming 
pyruvate into lactate was found to be down-regulated in 
both treatments suggesting that pyruvate was further 
processed into the TCA cycle instead of being 
transformed into lactate.  
 
Table 2. Changes in the expression of enzymes involved in mitochondrial glucose metabolism after treatment with 
azathioprine and taxol for 48 h as measured by quantitative proteomics. 
 
TCA CYCLE Azathioprine Taxol
Citrate synthase, mitochondrial  CS ↓ 1.52 
Aconitate hydratase  ACO2 ↑ 1.41 ↓ 1.23 
Dihydrolipoyl dehydrogenase DLD ↓ 1.48 
Alpha-ketoglutarate dehydrogenase complex dihydrolipoyl 
succinyltransferase  DLST ↓ 1.23 ↓ 1.70  
2-oxoglutarate dehydrogenase OGDH ↓ 1.37 
Beta-succinyl CoA synthetase SUCLA2 ↓ 1.25 
Succinate dehydrogenase complex SDHA ↓ 2.43 
SDHB ↓ 1.51 
Fumarate hydratase FH ↓1.27 
Malate dehydrogenase  
MDH1 ↓ 1.80 
MDH2 ↓ 1.22 
OXIDATIVE PHOSPHORYLATION Azathioprine Taxol
NADH dehydrogenase (complex I) 
NDUFV1  ↑ 1.54 
NDUFV2  ↓ 1.45 
NDUFS1  ↓ 1.73 
NDUFS7  ↓ 1.31 
NDUFB10  ↓ 1.29 
Succinate dehydrogenase complex (complex II) SDHA ↓ 2.43 
 SDHB ↓ 1.51 
Coenzyme Q – cytochrome c reductase (complex III) 
CYCS  ↓ 1.61 
UQCRC1  ↓ 1.42 
UQCRB  ↑ 1.62 
Cytochrome c  oxidase (complex IV) 
COX17  ↓ 2.00 
COX6C  ↓ 1.62 
COX6A1 ↑ 1.47  
COX5A  ↓ 1.39 
COX5B ↑ 1.37  
ATP synthase (complex V) 
ATP5A1 ↓ 1.51 ↓ 1.16 
ATP5F1 ↓ 1.70 ↓ 1.51 
ATP5H ↑ 1.56  
ATP5J ↑ 1.36  
ATP5B  ↑ 2.36 
Taxol  treatment  remarkably  decreased  the  expression  of  enzymes  of  the  TCA  cycle  and  oxidative  phosphorylation. 
Enzymes that show increased expression after treatment are shown in red, and enzymes that are decreased are shown 
in green. Number  indicates  the  fold  increase or  fold decrease  in protein expression  in chemotherapy‐treated versus 
vehicle‐treated hTERT‐BJ1 fibroblasts. 
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Figure 4. Taxol treatment alters several cellular metabolic pathways and induces autophagy and senescence in hTERT‐
BJ1 fibroblasts. (A) Summary of changes observed in the expression of numerous metabolic enzymes after treatment with taxol for
48 h, as measured by quantitative proteomics. Taxol treatment increased the expression of enzymes involved in glycolysis, pentose
phosphate,  and  hexosamine  biosynthesis  and  lipid  synthesis  pathways  in  detriment  of  those  involved  in  gluconeogenesis  and
mitochondrial metabolism  (TCA  cycle,  oxidative  phosphorylation,  and mitochondrial  β–oxidation).  Enzymes  that  show  amplified
expression after taxol treatment are shown in red, and enzymes that are decreased are shown in green. Cellular metabolic pathways
that may be up‐regulated are boxed  in  red, and  those  that may be down‐regulated are boxed  in green.  (B) Summary of  changes
observed in the expression of numerous autophagy and senescence‐related proteins after treatment with taxol for 48 h, as measured
by quantitative proteomics. Taxol amplified  the expression of proteins  involved  in  senescence, autophagy, mitophagy and vesicle
formation and trafficking. Proteins that show increased expression after treatment are shown in red. (C) Ingenuity Pathway Analysis
of azathioprine and taxol‐treated hTERT‐BJ1 fibroblasts predicted p53, TFEB and CCL5 to be activated in these cells. 
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Table 3. Changes in the expression of Nrf2-target proteins and other proteins involved in the antioxidant response 
after treatment with azathioprine and taxol for 48 h as measured by quantitative proteomics and indicated by IPA 
analysis. 
 
NRF2-MEDIATED ANTIOXIDANT RESPONSE Azathioprine Taxol 
 ATP-binding cassette, sub-family C (CFTR/MRP),    member 1 ABCC1 ↓ 2.34 
 Actin, alpha 2, smooth muscle, aorta ACTA2 ↑ 1.34 ↑ 1.78 
 Actin, beta ACTB ↑ 1.30 
 Actin, alpha, cardiac muscle 1 ACTC1 ↑ 1.75 ↑ 1.20 
 Carbonyl reductase 1 CBR1 ↑ 1.29 
 Chaperonin containing TCP1, subunit 7 (eta) CCT7 ↑ 2.89 
 DnaJ (Hsp40) homolog 
DNAJA1 ↑ 1.61 ↓ 9.61 
DNAJB11 ↓ 1.34 
DNAJC8 ↓ 1.79 ↓ 1.58 
DNAJC13 ↓ 4.30 
 Epoxide hydrolase 1, microsomal (xenobiotic) EPHX1 ↑ 2.06 
 Ferritin, light polypeptide FTL ↑ 1.61 ↑ 6.97 
 Glutathione S-transferase 
GSTK1 ↑ 1.34 
GSTO1 ↑ 1.57 
GSTP1 ↓ 1.53 
Heme oxygenase (decycling) 1 HMOX1 ↑ 4.48 ↑ 2.83 
 Mitogen-activated protein kinase 3 MAPK3 ↑ 1.54 
 Peptidylprolyl isomerase B (cyclophilin B) PPIB ↑ 1.60 ↑ 1.36 
 Peroxiredoxin 1 PRDX1 ↑ 1.68 
 Protein kinase C, alpha PRKCA ↑ 1.96 
 Related RAS viral (r-ras) oncogene homolog RRAS ↑ 2.44 
 Superoxide dismutase 1, soluble SOD1 ↑ 1.48 
 Superoxide dismutase 2, mitochondrial SOD2 ↑ 1.69 ↓ 1.87 
 Sequestosome 1 SQSTM1 ↑ 3.50 
 Thioredoxin TXN ↑ 2.75 
 Thioredoxin reductase 1 TXNRD1 ↑ 2.66 
Valosin-containing protein VCP ↓ 1.29 
ANTIOXIDANTS (OTHER) Azathioprine Taxol 
Aminopeptidase N ANPEP ↑ 1.78 ↑ 1.56 
Glutaredoxin-1 GLRX ↑ 1.25 
Glutathione peroxidase  GPX8 ↓ 1.85 
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Figure  5.  Pathway  analysis  of  differentially
expressed  proteins  in  hTERT‐BJ1  fibroblasts
treated with  azathioprine  or  taxol  compared  to
vehicle‐treated  cells.  Ingenuity  Pathway  Analysis
showed canonical pathways significantly altered by
the proteins differentially expressed  in hTERT‐BJ1
fibroblasts  treated with azathioprine or  taxol  (P <
0.05). The p value for each pathway is indicated by
the bar and is expressed as ‐1 times the log of the
p  value.  Green  coloured  bars  show  a  predicted
inhibition of  the pathway  (z  score  <‐1.9)  and  red
coloured bars indicate a predicted activation of the
pathway (z score >1.9). 
Peroxidasin PXDN ↑ 3.57 
Peroxiredoxin 
PRDX4 ↑ 1.50 
PRDX5 ↑ 1.33 
PRDX6 ↓ 1.23 
Chemotherapy mostly  increased  the expression of proteins  involved  in antioxidant  response, mainly  in  taxol‐treated 
fibroblasts. Proteins that show amplified expression after treatment are shown in red, and proteins that are decreased 
are shown in green. Number indicates the fold increase or fold decrease in protein expression in chemotherapy‐treated 
versus vehicle‐treated hTERT‐BJ1 fibroblasts. 
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Nevertheless, LDH is an enzyme that exhibits feedback 
inhibition, by which high lactate concentrations can 
suppress it. In fact, MCT4, the monocarboxylate 
transporter responsible for the secretion of lactate, turned 
out to be up-regulated in taxol-treated hTERT-BJ1 cells, 
and regarding the further processing of pyruvate into 
acetyl-CoA and the citric acid (TCA) cycle, the 
expression of practically all enzymes were found to be 
down-regulated in taxol-treated fibroblasts compared to 
vehicle indicating a dramatic down-regulation of 
mitochondrial metabolism. A similar down-regulation 
trend was observed in numerous proteins involved in all 
oxidative phosphorylation complexes (Table 2) and 
mitochondrial function proteins (Table S1). Finally, 
several enzymes involved in mitochondrial fatty acid β-
oxidation were also identified as down-regulated, and a 
few enzymes involved in fatty acid biosynthesis, up-
regulated (Table S2). Other metabolic changes included 
enzymes of the oxidative pentose phosphate pathway, 
responsible for the generation of antioxidant power 
(NADPH), the hexosamine  synthesis  pathway,  account- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
able for the production of amino sugars used for the 
synthesis of glycoproteins, glycolipids and 
proteoglycans, and a few enzymes involved in the 
generation of ketone bodies (Table 1 and 5). Figure 4A 
summarises all changes observed in the expression of 
metabolic enzymes in taxol-treated fibroblasts and their 
contribution to different cellular metabolic pathways. 
 
IPA revealed glycolysis, gluconeogenesis and pentose 
phosphate pathway as altered canonical pathways in 
both azathioprine and taxol treatments. Similarly, IPA 
revealed mitochondrial dysfunction, TCA cycle, and 
PPARα/RXRα activation, responsible for ketone body 
production and fatty acid metabolism, as two of the top 
canonical pathways affected by both treatments, and 
oxidative phosphorylation and fatty acid β-oxidation, as 
altered pathways also in taxol-treated cells (Figure 5 
and Table S5). The toxicity impact of both drugs 
extensively involved mitochondrial dysfunction and 
damage, and also fatty acid metabolism and 
PPARα/RXRα activation (Figure 6 and Table S6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  6.  Toxicity  effects  of  differentially  expressed  proteins  in  hTERT‐BJ1  fibroblasts  treated  with
azathioprine or taxol compared to vehicle‐treated cells.  Ingenuity Pathway Analysis showed  toxicity  functions
significantly enriched by the proteins differentially expressed in hTERT‐BJ1 fibroblasts treated with azathioprine or taxol
(P < 0.05). The p value for each pathway is indicated by the bar and is expressed as ‐1 times the log of the p value. 
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Table 4. Changes in the expression of proteins involved in myofibroblastic transformation and muscle-related 
proteins after treatment with azathioprine and taxol for 48 h as measured by quantitative proteomics. 
 
CANCER-ASSOCIATED FIBROBLAST AND MUSCLE-RELATED PROTEINS Azathioprine Taxol
Actin, alpha, cardiac muscle ACTC1 ↑ 1.75 ↑ 1.20 
Actin, alpha 2, aortic smooth muscle (αSMA) ACTA2 ↑ 1.34 ↑ 1.78 
Caldesmon CALD1  ↑ 2.49 
Calponin 
CNN1  ↑ 2.76 
CNN2 ↑ 1.81 ↑ 2.76 
CNN3 ↓ 1.28 ↑ 2.46 
Desmin DES ↑ 1.21 ↓ 1.79 
Dysferlin DYSF ↑ 1.24 
Fibroblast activation protein FAP ↑ 1.74 ↑ 1.56 
Fibronectin 1 FN1 ↑ 2.02 ↑ 2.03 
Filamin 
FLNA ↓ 1.92 ↑ Infinity 
FLNB ↓ 1.23  
FLNC  ↑ 1.56 
Moesin MSN ↑ 1.37 ↑ 1.60 
Myoferlin MYOF ↑ 4.15 ↑ 1.95 
Myosin 
MYH4  ↑ 1.62 
MYH9 ↑ 1.64  
MYH10 ↑ 1.37  
MYH11 ↑ 1.47 ↑ 1.90 
MYH14 ↓ 3.06  
MYO1B  ↓ 1.72 
MYO1C ↑ 2.21 ↑ 1.59 
MYO10 ↑ 1.37  
MYO18B ↓ 1.50 ↑ 2.62 
Myosin, light polypeptide kinase MYLK  ↑ 1.88 
Myosin phosphatase Rho interacting protein  MPRIP  ↑ 1.45 
Myosin regulatory light polipeptides 
MYL6 ↑ 1.33 ↑ 1.74 
MYL9  ↑ 1.77 
MYL12A  ↑ 2.21 
Palladin PALLD  ↑ 3.88 
Platelet-derived growth factor receptor, beta PDGFRB  ↑ 1.59 
Prolyl 4-hydroxylase 
P4HA1  ↑ 3.14 
P4HA2 ↓ 1.32 ↓ 2.50 
P4HB ↓ 1.76  
Talin 
TLN1 ↑ 1.46 ↑ 2.95 
TLN2 ↓ 1.80  
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To recapitulate, the previously identified chemotherapy-
induced metabolic stress in stromal fibroblasts is clearly 
detected by quantitative proteomics and it represents not 
only an increase in glycolysis and a reduction in 
mitochondrial function, as observed in our previous 
study, but also affects other metabolic pathways, 
including hexosamine synthesis and pentose phosphate 
pathways, fatty acid metabolism and ketogenesis.  
 
2. Antioxidant response and stress-related pathways 
 
Another feature of the catabolic tumour stroma is the 
induction of oxidative stress, which can be induced by 
chemotherapy in cancer cells and also healthy tissues 
(Figure 1) [18, 19]. Particularly, we previously showed 
increased ROS production and antioxidant response in 
hTERT-BJ1 fibroblasts after treatment with taxol [11]. 
We have seen in this study that several enzymes of the 
oxidative branch of the pentose phosphate pathway, 
which is responsible for the generation of antioxidant 
power (NADPH), were up-regulated in chemotherapy-
treated stromal fibroblasts. Thus, we sought for other 
antioxidant response proteins in the proteomics datasets. 
The expression of numerous proteins involved in Nrf2-
mediated antioxidant response and other antioxidant 
proteins was significantly altered, in most cases up-
regulated (Table 3), suggesting an activation of the 
pathway in both azathioprine and taxol-treated hTERT-
BJ1 fibroblasts, although it was found to be notably 
higher in taxol-treated cells.  
 
A higher presence of antioxidant response proteins was 
further confirmed using IPA, which revealed Nrf2-
mediated antioxidant response to be one of the top 
canonical pathways affected by azathioprine and taxol 
treatments, although z score values demonstrated a 
significant activation of  this  pathway  exclusively  in  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
taxol-treated fibroblasts. Similarly, taxol-treated cells 
showed altered glutathione and thioredoxin antioxidant 
pathways (Figure 3E and 5, and Table S5). The toxicity 
of these chemotherapeutic drugs also involved oxidative 
stress. HIF signalling, which is activated in response to 
stress and a central player in the regulation of cellular 
metabolism, was also identified as a toxic effect of 
azathioprine treatment (Figure 6 and Table S6), and had 
been previously identified as activated in hTERT-BJ1 
fibroblasts treated with azathioprine and taxol [11]. 
Thus, proteomics analysis clearly detects an activation 
of the antioxidant response after treatment with 
chemotherapy. 
 
3. Myofibroblastic differentiation 
 
Cancer-associated fibroblasts are commonly identified 
by their expression of alpha smooth muscle actin 
(αSMA) [20] (Figure 1). Indeed, we previously showed 
up-regulation of αSMA by immunoblotting in taxol-
treated hTERT-BJ1 [11]. Quantitative proteomics 
profiling of azathioprine and taxol-treated hTERT-BJ1 
fibroblasts also revealed a significantly higher presence 
of αSMA and many other myofibroblastic markers, 
such as fibroblast activation protein (FAP) or vimentin, 
as well as muscle-related proteins compared to the 
vehicle-treated control (Table 4).  
 
Myofibroblasts are mostly responsible for the presence 
of fibrosis [21], and the toxicity functions of these 
chemotherapeutic drugs involved tissue fibrosis, as 
analysed by IPA (Figure 6 and Table S6). Therefore, 
chemotherapy can independently induce the 
differentiation of hTERT-BJ1 fibroblasts into cancer-
associated fibroblasts, which can be detected by a 
numerous increase of myofibroblastic markers in 
quantitative proteomics analysis.  
 
 
    
Transgelin 2 TAGLN2  ↑ 1.93 
Tropomyosin 
TPM1 ↓ 2.63 ↓ 4.23 
TPM2 ↑ 1.24  
TPM3 ↑ 1.43  
TPM4  ↑ 2.12 
Vimentin VIM ↑ 1.72 ↑ 1.76 
Chemotherapy enormously  increased  the expression of proteins  involved  in CAF  transformation. Proteins  that  show 
amplified expression after treatment are shown  in red, and proteins that are decreased are shown  in green. Number 
indicates  the  fold  increase  or  fold  decrease  in  protein  expression  in  chemotherapy‐treated  versus  vehicle‐treated 
hTERT‐BJ1 fibroblasts. 
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4. Autophagy and senescence 
 
Autophagy and senescence represent a common 
response to stresses such as exposure to DNA-damaging 
exogenous cytotoxic agents, including chemotherapy or 
radiation [22, 23]. Indeed our previous study indicated 
that azathioprine and taxol induce autophagic vesicle 
formation and increase β-galactosidase activity in 
stromal fibroblasts [11]. Thus, to further examine 
changes in autophagy and senescence upon 
chemotherapeutic exposure,  the  differential  expression  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
of several autophagy, mitophagy and lysosomal markers 
was analysed using the proteomics datasets. Numerous 
autophagy and senescence markers such as 
sequestrosome 1, also known as p62, cathepsin B or the 
lysosomal enzyme β-galactosidase were found to be up-
regulated in either azathioprine or taxol treatments 
(Table 5). In addition, DNM1L, a protein involved in 
mitochondrial fission, was up-regulated in taxol-treated 
hTERT-BJ1 fibroblasts, and OPA1, a protein involved 
in mitochondrial fusion, was down-regulated in 
azathioprine-treated cells. Likewise, VAT1, a vesicle 
Table 5. Changes in the expression of autophagy, mitophagy and senescence markers and ketogenesis enzymes 
after treatment with azathioprine and taxol for 48 h as measured by quantitative proteomics. 
 
AUTOPHAGY MARKERS Azathioprine Taxol
Cathepsin 
CATB ↑ 1.56 ↑ 1.55 
CATD  ↑ 1.62 
Lysosomal-associated membrane protein 1 LAMP1 ↑ 1.55  
Microtubule-associated protein 1 light chain 3 beta MAP1LC3B  ↑ 1.58 
Sequestrosome 1 (p62) SQSTM1  ↑ 3.50 
MITOPHAGY MARKERS Azathioprine        Taxol 
Dynamin-1-like protein (fission) DNM1L  ↑ 1.71 
Dynamin-like 120 kDa protein, mitochondrial (fusion) OPA1 ↓ 1.44  
LYSOSOMAL PROTEINS (OTHER) Azathioprine Taxol
Cation-dependent mannose-6-phosphate receptor M6PR  ↑ 2.38 
Cation-independent mannose-6-phosphate receptor IGF2R ↑ 3.58 ↑ 1.88 
Galactosidase, beta 1 GLB1 ↑ 1.53  
Late endosomal/lysosomal adaptor, MAPK and mTOR activator 
1 LAMTOR1 ↑ 1.85 
 
Lysosome membrane protein 2 SCARB2 ↑ 1.63 ↑ 1.49 
N-acetylglucosamine-6-sulfatase  GNS  ↑ 1.43 
Prenylcysteine oxidase 1 PCYOX1  ↑ 1.55 
Prosaposin PSAP ↑ 2.21 ↑ 2.13 
KETOGENESIS Azathioprine Taxol
Hydroxyacyl-CoA dehydrogenase 
HADH ↓ 1.43 
HADHA ↓ 1.57 
HADHB ↑ 1.36 
3-Hydroxymethyl-3-methylglutaryl-CoA lyase HMGCL ↑ 1.67 
Chemotherapy incremented the expression of proteins involved in autophagy and senescence. Proteins that show 
increased expression after treatment are shown in red, and proteins that are decreased are shown in green. Number 
indicates the fold increase or fold decrease in protein expression in chemotherapy-treated versus vehicle-treated hTERT-
BJ1 fibroblasts. 
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membrane protein that inhibits mitochondrial fusion, 
was up-regulated in both treatments, suggesting that 
mitophagy might be also activated in response to 
chemotherapy (Table 5 and Table S3).  
 
During autophagy, protein and lipid degradation occur, 
the latter leading to the generation of ketone bodies. A 
long list of up-regulated proteins involved in vesicle 
formation and trafficking, in protein ubiquitination 
pathway and proteasomal degradation, and a few 
enzymes involved in ketogenesis were also identified 
(Table 5, S3 and S4). The boost in vesicle formation and 
trafficking proteins could explain the greater presence of 
enzymes involved in fatty acid synthesis and hexosamine 
biosynthesis (Figure 4A and Table 1 and S2). The 
observed effects of taxol treatment on autophagy, 
mitophagy and senescence are summarised in Figure 4B. 
 
IPA analysis confirmed an alteration of ketogenesis in 
fibroblasts exposed to azathioprine (Figure 5 and Table 
S5). IPA also showed a robust inhibitory effect of 
azathioprine and taxol on EIF2 signalling, responsible for 
protein synthesis, as measured by z score, and also 
revealed an alteration in the regulation of eIF4 and 
p70S6K signaling and in the protein ubiquitination 
pathway. Finally, PPARα/RXRα activation, Rho, 
caveolar and clathrin-mediated signalling pathways, all 
involved in vesicle trafficking and motility, and the 
mTOR signalling, known for its role in autophagy, mito-
chondrial metabolism and lipid metabolism, as well as 
cytoskeleton dynamics, were some of the top canonical 
pathways altered by chemotherapy, (Figure 3E, 5, and 
Table S5). Interestingly, p53,  known  mediator  of  senes- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cence, was predicted to be activated in both azathioprine-
treated and taxol-treated hTERT-BJ1 cells according to 
IPA, and TFEB, a transcriptor factor that coordinates the 
expression of lysosomal hydrolases, membrane proteins 
and genes involved in autophagy, was also predicted to 
be activated by taxol treatment (Figure 3F and 4C). Our 
previous study also reported an increased expression of 
p53 in hTERT-BJ1 fibroblasts treated with azatioprine 
and taxol by immunoblotting [11]. 
 
Thus, quantitative proteomics analysis reveals a higher 
presence of markers of autophagy and senescence and 
proteins involved in protein degradation and vesicle 
trafficking in hTERT-BJ1 fibroblasts, upon treatment.  
 
5. Inflammation  
 
Senescent cells dramatically alter their secretome, 
enriching it with pro-inflammatory cytokines and matrix 
metalloproteinases.  This senescence-associated 
secretory phenotype (SASP) can lead to chronic 
inflammation, which is a hallmark of aging [17]. 
Stromal fibroblasts secrete inflammatory cytokines 
when in contact with cancer cells [24]. Chemotherapy is 
also able to induce cytokine production in healthy 
tissues [12], and in particular taxol treatment induces 
IL6 secretion in stromal fibroblasts (Figure 1) [11]. 
STAT3, a known inducer of inflammation in response 
to stress [25, 26] was found significantly up-regulated 
in both azathioprine (1.69 fold increase) and taxol 
treatments (2.35 fold increase) relative to vehicle. 
STAT3 signalling was found to be activated in response 
to taxol also in our previous study [11]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table  6.  Proteins of the catabolic stroma signature and their contribution to CAF transformation, metabolism, 
antioxidant response, autophagy and vesicle trafficking. 
 
CATABOLIC STROMA SIGNATURE Taxol Process 
 Ubiquitin-like modifier activating enzyme 1 UBA1 ↑ 2.36 Protein degradation 
 26S protease regulatory subunit 8  PSMC5 ↑ 3.17 Protein degradation 
 Cation-independent mannose-6-phosphate receptor IGF2R ↑ 1.88 Autophagy 
Synaptic vesicle membrane protein VAT-1 VAT1 ↑ 2.44 Vesicle trafficking / oxidoreductase /inhibits mitochondrial fusion 
Heme oxygenase (decycling) 1 HMOX1 ↑ 2.83 Antioxidant / oxidoreductase 
Calponin 2 CNN2 ↑ 2.76 Myofibroblastic differentiation 
Talin 1 TLN1 ↑ 2.95 Myofibroblastic differentiation 
Glucosamine-6-phosphate deaminase 1 GNPDA1 ↑ 2.46 Carbohydrate metabolism 
Glucose-6-phosphate dehydrogenase G6PD ↑ 2.69 
Carbohydrate metabolism /generates 
antioxidant power 
Fatty acid synthase FASN ↑ 1.77 Fatty acid metabolism 
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Figure 7. Clinical correlations of UBA1 expression and the UBA1, PSMC5, IGF2R, VAT1, HMOX1, CNN2, TLN1, GNPDA1,
G6PD and FASN signature in chemotherapy‐treated breast cancer patients. (A) Correlations of UBA1 expression with relapse‐
free survival, distant metastasis‐free survival and overall survival  in breast cancer.  (B) Correlations of  the catabolic stroma signature
with  relapse‐free  survival,  distant  metastasis‐free  survival  and  overall  survival  in  breast  cancer.  All  graphs  are  calculated  using
microarray data from 425, 122 and 69 chemotherapy‐treated breast cancers, respectively, determined using an online survival analysis
tool. Kaplan‐Meier correlations are plotted for high (above median, in red) and low (below median, in black) gene expression. 
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Figure 8. Clinical correlations of UBA1 expression and the UBA1, PSMC5, IGF2R, VAT1, HMOX1, CNN2, TLN1, GNPDA1,
G6PD and FASN signature  in chemotherapy‐treated  lung, gastric and ovarian cancer patients.  (A) Correlations of UBA1 
expression with overall survival in lung and gastric cancer, and with progression‐free survival in ovarian cancer. (B) Correlations of the 
catabolic stroma signature with overall survival  in  lung and gastric cancer, and with progression‐free survival  in ovarian cancer. All 
graphs are calculated using microarray data from 176 chemotherapy‐treated lung cancers, 153 5‐FU‐based adjuvant therapy‐treated 
gastric  cancers,  and  229  paclitaxel‐treated  ovarian  cancers,  determined  using  an  online  survival  analysis  tool.  Kaplan‐Meier 
correlations are plotted for high (above median, in red) and low (below median, in black) gene expression. 
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Interestingly, several pathways involved in the 
inflammatory process such as IL8, acute phase 
response, leukocyte extravasation or Fcγ receptor-
mediated phagocytosis signalling were amongst altered 
canonical pathways in both azathioprine-treated and 
taxol-treated hTERT-BJ1 cells relative to vehicle, 
according to IPA. N-formyl-Met-Leu-Phe (fMLP) 
signalling was also found to be altered in taxol-treated 
fibroblasts (Figure 3E and 5 and Table S5). Most of 
these pathways were clearly activated in taxol-treated 
fibroblasts as indicated by z score values, suggesting an 
induction of the inflammatory response in 
chemotherapy-treated stromal fibroblasts. Likewise, the 
chemokine (C-C motif) ligand 5 (CCL5 or RANTES), 
which plays a role in recruiting leukocytes into 
inflammatory sites, was identified as an upstream 
regulator in both treatments, particularly activated in 
taxol-treated fibroblasts (Figure 3F and 4C). Finally, 
acute phase response, which occurs soon after the onset 
of an inflammatory process, was identified as one of the 
toxic effects of both drugs (Figure 6 and Table S6). 
Therefore, pathway analysis of the proteomics results 
indicates an induction of the inflammatory response in 
stromal fibroblasts after exposure to chemotherapy. 
 
Differentially up-regulated proteins in taxol-treated 
fibroblasts correlate with recurrence, metastasis and 
poor cancer survival 
 
To further investigate the clinical implications of our 
proteomics datasets, we decided to test the impact of 
over-expressed proteins in taxol-treated hTERT-BJ1 
fibroblasts in cancer prognosis. To do so, we used an 
on-line survival analysis tool that uses microarray gene 
expression data from multiple studies on breast, 
ovarian, lung and gastric cancer [16], which was 
suitable to our purpose since taxol is a 
chemotherapeutical drug currently used as therapy for 
most of these malignancies. Only those proteins with a 
fold change difference of 1.75 or higher and p values of 
<0.05 (ANOVA) compared to vehicle were used for 
survival analyses. The expression of several proteins 
was found to correlate with survival in breast, ovarian, 
gastric and lung cancer patients. In particular, high 
expression of ubiquitin-like modifier activating enzyme 
1 (UBA1), implicated in protein catabolism and 
degradation, showed a striking correlation with poor 
relapse-free survival, distant metastasis-free survival 
and overall survival in breast cancer patients previously 
treated with chemotherapy (425, 122 and 69 patients, 
respectively) (Figure 7A). The same correlation was not 
observed when patients who did not receive systemic 
treatment were considered (1000, 533 and 375 patients, 
respectively) (Figure S2A). Similarly, high expression 
of UBA1 correlated with poor overall survival in lung 
and gastric cancer patients previously treated with 
chemotherapeutic drugs (176 and 153 patients, 
respectively), and with progression-free survival in 
ovarian cancer patients particularly treated with 
paclitaxel (229 patients) (Figure 8A). Once more, the 
correlation was lost when patients who did not receive 
systemic treatment were considered in lung cancer (227 
patients) or when patients who underwent only surgery 
were examined in gastric cancer (174 patients) (Figure 
S3A). No data from untreated ovarian cancer patients 
was available.  
 
A taxol-induced catabolic stroma signature was created 
comprising UBA1, and other proteins representative of 
the catabolic CAF-like phenotype, including PSMC5, 
and VAT1, involved in catabolism and vesicle 
trafficking, several metabolic enzymes including FASN, 
G6PD and GNPDA, an autophagy marker, IGF2R, the 
oxidoreductase HMOX1, and myofibroblastic markers 
including CNN2 and TLN1. See Table 6 for details and 
abundances of these proteins in taxol-treated fibroblasts. 
That catabolic stroma signature showed a strong 
correlation with survival in treated patients (Figure 7B 
and 8B), whereas that correlation was not seen in non-
treated patients (Figure S2B and S3B). Hence, the over-
expression of proteins upon treatment with taxol is 
strongly linked to poor survival, treatment failure and 
metastasis in breast, lung, gastric and ovarian cancers. 
Interestingly, most markers used for the signature are 
also proteins found to be significantly up-regulated in 
azathioprine-treated hTERT-BJ1 fibroblasts relative to 
vehicle, including IGF2R, PSMC5, VAT1, HMOX1, 
CNN2, TLN1 and FASN (Tables 3, 4 5, S2, S3 and S4).  
Thus, we conclude that chemotherapy-mediated 
changes in the abundance of stromal proteins related to 
the CAF-like catabolic phenotype measured by 
quantitative proteomics associate with reduced survival, 
enhanced recurrence and metastasis incidence in several 
solid malignancies. 
 
DISCUSSION  
 
In this study we have analysed the impact of 
chemotherapy in the acquisition of the CAF-like, 
catabolic tumour stroma phenotype, which emerges in 
stromal fibroblasts in contact with cancer cells, and is 
characterised by increased glucose uptake, lactate 
production and extracellular acidification, increased 
expression of αSMA, augmented production of ROS, an 
activation of the JNK/AP1, HIF1, TGFβ/SMAD, 
STAT3 and NFkB stress-induced pathways, senescence 
and autophagy, and a greater secretion of inflammatory 
cytokines. To do so, we aimed at comprehensively 
characterising the cellular and metabolic changes that 
take place in stromal fibroblasts exposed to two 
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common chemotherapeutic drugs: azathioprine and 
taxol. Label-free quantitative proteomics and extensive 
bioinformatics analyses revealed a protein profile 
characteristic for chemotherapy-treated fibroblasts that 
included alterations in energy metabolism, antioxidant 
response, autophagy and senescence, vesicle formation 
and trafficking, protein degradation, myofibroblastic 
differentiation and inflammation.  
 
Proteomic map of the stromal catabolic state 
induced by chemotherapy 
 
The main protein set whose expression was altered in 
chemotherapy-treated fibroblasts was that of enzymes. 
Azthioprine and taxol effects on the glycolytic function 
of stromal fibroblasts were characterised in a previous 
study, which showed the induction of a glycolytic switch 
in hTERT-BJ1 fibroblasts via increasing their lactate 
production and extracellular acidification, and decreasing 
their ATP content [11]. We know now that this behaviour 
is likely to be a result of the observed up-regulation of 
enzymes involved in glycolysis and down-regulation of 
mitochondrial respiration enzymes. Indeed, our proteo-
mic analysis shows alterations not only in glycolysis but 
also in pyruvate conversion to acetyl-coenzyme A and 
the TCA cycle. The reduction in ATP production through 
decreased TCA cycle activity and mitochondrial 
respiration may be forcing a metabolic switch that allows 
the cell to obtain energy from alternative metabolic 
processes such as glycolysis or protein catabolism. This 
metabolic remodelling also includes an alteration of other 
pathways of the carbohydrate metabolism, such as the 
phosphate pentose and hexosamine biosynthesis 
pathways, and several pathways of the fatty acid 
metabolism. In line with our findings, a recent study 
demonstrates that as an adaptive response to mito-
chondrial respiratory chain dysfunction and ATP 
deficiency, human fibroblasts up-regulate the expression 
of glycolytic enzymes, suggesting the induction of 
anaerobic glycolysis and a cellular catabolic state, in 
particular protein catabolism, together with autophagy 
[27].  
 
According to our data, the hexosamine biosynthesis 
pathway is also altered in chemotherapy-treated 
fibroblasts, which goes in line with the increased 
presence of proteins involved in vesicle formation and 
trafficking. GNPDA1 is an enzyme of the hexosamine 
biosynthesis pathway, the end-products of which are 
used for the synthesis of membrane components such as 
glycolipids and proteoglycans. However, GNPDA1 
catabolizes a reversible conversion between D-fructose-
6-phosphate and D-glucosamine-6-phosphate, and 
therefore could also be used in reverse to produce 
substrates for glycolysis, by sacrificing structural 
components of the cell.  
 
The phosphate pentose pathway is a metabolic pathway 
also altered by chemotherapy. During the oxidative 
phase of the pentose phosphate pathway, most of the 
reducing power of the cell is generated as NADPH. 
Taxol-treated fibroblasts show increased levels of the 
initial rate-limiting enzyme of the pentose phosphate 
pathway, glucose-6-phosphate dehydrogenase 
(G6PDH), which converts glucose-6-phosphate and 
NADP+ into 6-phosphoglucono-δ-lactone and NADPH. 
NADPH is also necessary for lipid and nucleic acid 
biosynthesis, and its re-oxidation to NADP+ constitutes 
an essential step to prevent damage by oxidative stress. 
Increased amounts of NADPH go in line with the up-
regulation of several proteins involved in antioxidant 
response, such as Nrf2-mediated antioxidant response 
proteins, as well as the greater ROS levels that we have 
previously seen in hTERT-BJ1 fibroblasts after taxol 
treatment [11]. The accumulation of ROS as a 
consequence of mitochondrial dysregulation during 
aging is also associated with DNA damage [28]. 
Therefore, oxidative stress and aging can be coupled in 
a positive feedback mechanism that accelerates cellular 
damage and generates a permissive metabolic 
microenvironment for cancer development and 
progression [5, 28-30].  
 
Oxidative stress in healthy cells and tissues by most 
current anti-cancer therapies is thought to occur via p53 
activation, which causes mitochondrial dysfunction, ROS 
production and downstream STAT3 signalling, 
promoting inflammation-related cancer [19, 26]. Our 
proteomics results revealed a predicted activation state of 
p53, mitochondrial dysfunction, increased expression of 
antioxidant proteins, autophagy and senescence markers, 
and specifically STAT3 up-regulation in chemotherapy-
treated fibroblasts compared to vehicle. Our observations 
in vesicle trafficking and protein transport and 
degradation also suggest a general intensification in the 
transport of proteins and other cellular components to 
autophagosomes and lysosomes. Indeed, taxol is able to 
induce the formation of autophagic vesicles in stromal 
fibroblasts [11]. By increasing that transport, the stressed 
cell could be attempting to remove dysfunctional 
organelles such as mitochondria and other molecules that 
accumulate as a result of oxidative damage, or 
alternatively it could also be trying to retrieve molecules 
for re-utilisation in detriment of de novo protein 
synthesis, which is more energy consuming. 
 
Myofibroblasts are abundant components of the reactive 
tumour microenvironment and are mostly accountable 
for the development of fibrosis [21], one of the side-
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effects of cancer therapy [31]. Fibroblast-to-
myofibroblast differentiation increases in the stroma 
with age as well, resulting in an increased incidence of 
fibrosis-associated diseases, such as cancer [32]. Here, 
we report that exposure to chemotherapy can 
independently induce the transformation of fibroblasts 
into CAFs, by detecting an increase in the presence of 
numerous markers of myofibroblastic differentiation as 
measured by quantitative proteomics.  
 
Finally, we identify several inflammation-related 
pathways as altered in taxol-treated fibroblasts, 
suggesting an induction of the inflammatory response. 
We previously described IL6 as one of the cytokines 
secreted by chemotherapy-treated fibroblasts and 
STAT3 target genes as being activated after treatment 
with taxol [11]. However, to comprehensively 
characterize the pro-inflammatory cytokines released by 
hTERT-BJ1 cells, secretome analysis should be 
performed for better insights.  
 
In the present study, proteomic analyses revealed the 
impact of chemotherapy in the acquisition of a catabolic 
CAF-like phenotype in stromal fibroblasts, gradually 
conforming an energy-rich, pro-inflammatory micro-
environment able to succour cancer cells in their battle 
for survival, in their purpose to metastasise, or even 
through which chemotherapy-damaged epithelial cells 
may become more susceptible to develop a fully 
malignant phenotype, giving rise to a new cancer. Taxol 
induces the catabolic stroma phenotype to a bigger extent 
than azathioprine. The different nature of these two drugs 
and the concentrations selected for the study could account 
for their different impact on catabolic remodelling.  
 
Clinical implications of the catabolic stroma 
signature 
 
Quantitative proteomics allowed us to obtain a protein 
profile characteristic for fibroblasts exposed to 
azathioprine and taxol, which suggests a general 
alteration in their energy metabolism and a shift towards 
glycolysis and catabolic processes: a whole metabolic 
reprogramming to adapt to chemotherapy-driven 
mitochondrial dysfunction and oxidative stress. Likewise, 
the quantitative proteomics analysis allowed us to 
identify biomarkers of this stromal catabolic state, which 
were further analysed for their potential clinical 
implications. We generated a signature to figure out 
whether the chemotherapy-induced catabolic state in the 
stroma would have prognostic value. Indeed, the 
catabolic phenotype in stromal fibroblasts strikingly 
correlated with poor survival, treatment failure and 
metastatic growth in a set of breast, ovarian, lung and 
gastric cancer patients who were subject to chemo-
therapy, correlation that was lost when untreated patients 
were considered. 
 
Our knowledge of the role of healthy stromal cells in 
metastasis and in particular in the emergence of 
therapy-related malignancies is still very scarce. A piece 
of evidence for chemotherapy-induced tumour-
promoting paracrine activities of non-malignant cells 
has only been recently published, showing that pre-
treatment of tumour-free mice with a single dose of 
doxorubicin is sufficient to stimulate the engraftment of 
lung carcinoma cells and to elevate the mitogenic 
activity of the serum from treated animals [12]. By 
label-free quantitative proteomics we detect the 
acquisition of a catabolic state in stromal cells due to 
chemotherapy-induced DNA damage, which potentially 
leads to the generation of an autophagic, nutrient-rich, 
senescent, pro-inflammatory microenvironment, the 
ideal niche to encourage the development of a 
secondary tumour or even a new carcinogenic process. 
However, the tumour-promoting function and the 
stability and reversability of the chemotherapy-induced 
CAF phenotype needs to be further investigated, as well 
as the differential expression of chemotherapy-induced 
catabolic stress markers on stromal fibroblasts and 
cancer cells in vivo. 
 
To conclude, proteomic analyses revealed a significant 
metabolic reprogramming in response to chemotherapy. 
Our data provide information about novel protein 
targets that might enable and support different stages of 
the tumorigenic process, thereby opening new doors for 
future research. Given the essential contribution of the 
catabolic tumour stroma in cancer progression, it 
emerges as a new interesting therapeutic target. A 
promising approach would be the preventive inhibition 
of the catabolic state transformation. Indeed, TGFβ-
induced myofibroblastic transformation in fibroblasts 
can be reversed by using antioxidants [33]. Most 
importantly, an antibody against fibroblast activation 
protein (FAP) is already being tested in clinical trials 
[34]. Therefore, inhibition of the catabolic stress in the 
tumour stroma and healthy tissues in parallel to 
conventional chemotherapy could help avoiding 
recurrence, metastasis and the growth of second primary 
tumours.  
 
MATERIALS AND METHODS 
 
Cell culture. All cell culture experiments were carried 
out using human foreskin fibroblasts immortalised with 
the human telomerase reverse transcriptase (hTERT-
BJ1 cells). hTERT-BJ1 fibroblasts were originally 
purchased from ATCC (CRL-4001) and maintained in 
DMEM media (D6546, Sigma) supplemented with 10 
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% fetal bovine serum (FBS) (F7524, Sigma), 100 
units/ml of penicillin, 100 µg/ml streptomycin (P0781, 
Sigma) and 1% Glutamax (#35050087, Life 
Technologies) at 37°C in a humidified atmosphere 
containing 5% CO2. 
 
Chemotherapeutical agents. Azathioprine (A4638, 
Sigma) and taxol or paclitaxel (Y0000698, Sigma) were 
used for this study at 100 µM and 100 nM, respectively. 
  
Sulforhodamone B (SRB) assay. SRB (S9012, Sigma) 
measures total biomass by staining cellular proteins. 
After 48 h treatment, cells were fixed in 10% 
trichloroacetic acid (T9159, Sigma) for 1h at 4°C, 
stained with SRB (S9012, Sigma) for 15 minutes, and 
washed 3 times with 1% acetic acid (27225, Sigma). 
The incorporated die was solubilized with 10 mM Tris 
Base, pH 8.8 (T1503, Sigma). Absorbance was 
spectrophotometrically measured at 562 nm in a 
FluoStar Omega plate reader (BMG Labtech). 
Background measurements were subtracted from all 
values.  
 
Label-free quantitative proteomics 
 
Chemicals and sample preparation. Formic acid, 
trifluoroacetic acid, ammonium formate (10 M), 
ammonium bicarbonate TCEP (Tris (2-
carboxyethyl)phosphine hydrochloride), MMTS 
(Methyl methanethiosulfonate)  and trypsin were all 
obtained from Sigma. HPLC gradient grade acetonitrile 
was obtained from Fisher Scientific. Briefly, 2 x 106 
hTERT-BJ1 fibroblasts were seeded in 150 cm plates 
until cells were attached. Cells were then treated with 
azathioprine or taxol at the concentrations indicated. As 
control, vehicle-treated cells were processed in parallel. 
After 48 hours of treatment, cells were lysed in RIPA 
buffer (R0278, Sigma) and kept at 4°C for 20 minutes 
with rotation. Lysates were cleared by centrifugation for 
10 minutes at 10,000 x g and supernatants were 
collected and kept frozen at -80°C. 
 
Protein digestion.  Lysate samples were thawed to room 
temperature and their concentrations equalised to 1 
µg/µL (50 µL volume) with RIPA buffer, and further 
processed for trypsin digestion by sequential reduction 
of disulphide bonds with TCEP and alkylation with 
MMTS. Briefly, 1 µL benzonase (Novagen) was added 
to the 50 µL aliquot and placed on ice for 15 minutes. 
The sample was then taken to dryness using a 
SpeedVac, and resuspended in 22.5 µL trypsin reaction 
buffer (40 mM ammonium bicarbonate and 9% 
acetonitrile). One µL of 50 mM TCEP solution was 
added to each sample, mixed briefly and placed on a 
heater block at 60°C for 60 minutes. After cooling to 
room temperature, 0.5 µL of 200 mM MMTS solution 
was added to each sample and allowed to react for 15 
minutes. Trypsin was added in two waves to ensure 
efficient digestion of the sample. Firstly, 20 µg of 
sequencing grade trypsin was resuspended in 1800 µL 
of trypsin reaction buffer; 225 µL of this solution were 
added to each sample for digestion, and the reactions 
were left at 37°C overnight with shaking (600 rpm). The 
following morning, a further aliquot of trypsin was 
added. Two ml of trypsin reaction buffer was added to 
20 µL of sequencing grade trypsin; 250 µL of this 
solution were added to each of the digest samples from 
overnight, and the reactions were left at 37°C for 4 
hours with shaking (600 rpm). Thirty-five µL 10% 
formic acid were added to the 500 µL digest sample 
(0.7% final concentration of formic acid) to stop the 
digestion. The digested solution was diluted in 7.5 mL 
of acetonitrile containing 0.3% formic acid. 
 
HILIC solid phase extraction (SPE) of peptides. 
PolyhydroxyethylA SPE 12 µm, 300A, 300mg 
cartridges (obtained from PolyLC) were used for the 
HILIC procedure. Prior to use, cartridges required an 
overnight soak in 50 mM formic acid followed by 
rinsing with water the following day. Cartridges were 
preconditioned with 2 mL of Buffer A (90% 
acetonitrile, 5 mM ammonium formate, pH 2.7) 
followed by 2 mL of Buffer B (5mM ammonium 
formate, pH 2.7) and finally re-equilibrated with 10 mL 
Buffer A. The diluted samples were loaded onto the 
cartridges and washed with a further 10 mL Buffer A. 
Finally, peptides were eluted in 1 mL Buffer C (9 parts 
Buffer B plus 1 part Buffer A) and the samples dried on 
a Speedvac to remove organic solvent prior to LC-
MS/MS analysis. 
 
LC-MS/MS analysis. Lyophilised digests were 
resuspended in 50 µL of 0.1% TFA to give an 
approximate concentration of 1 µg/µL. One µL 
injection volumes were used throughout resulting in an 
on-column peptide loading of approximately 1 µg per 
injection. Analysis was performed in quintuplicate for 
each sample. All LC-MS/MS analyses were performed 
on an LTQ Orbitrap XL mass spectrometer coupled to 
an Ultimate 3000 RSLCnano system (Thermo 
Scientific). One µL injection volumes were used 
throughout and samples loaded directly onto the 
analytical column, PepMap RSLC C18, 2 µm x 75 µm 
id x 50 cm (Thermo Scientific). The composition (v/v) 
of LC buffers were as follows; Buffer A - 99.9% water 
plus 0.1% formic acid and Buffer B  - 80% acetonitrile, 
19.9% water and 0.1% formic acid. Peptides were 
loaded directly onto the column at a flow rate of 400 
nl/min with an initial mobile phase composition of 1% 
B. The organic strength was increased linearly from 1% 
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to 22.5% B over 22.5 minutes again at 400 nl/min, 
followed by an increase to 24.8% B over the next 2.6 
minutes with a concomitant reduction in flow rate to 
300 nl/min, and to 39% B over a further 14 minutes. A 
further increase to 60% B over the next 5 minutes was 
followed by a ramp to 95% B over 2.5 minutes where it 
was held for a further 2 minutes. The column was then 
allowed to re-equilibrate to 1% B for a total analysis 
time of 74 minutes. The mass spectrometer was 
instructed to perform data dependent acquisition on the 
top six precursor ions, which were measured in the 
Orbitrap FTMS detector over the mass range 370–1200 
m/z, at a nominal resolution of 60,000. MS/MS spectra 
were acquired in the ion trap under CID conditions with 
normalized collision energy of 35, isolation width of 3 
Th, Q value of 0.25 and 30 ms activation time. Gas-
phase fractionation was performed on the five replicate 
injections such that MS/MS data was collected for 
precursor ion range 370-494 m/z Injection 1, 494-595 
m/z Injection 2, 595-685 m/z Injection 3, 685-817 m/z 
Injection 4 and 817-1200 m/z Injection 5. 
 
Statistical analysis. Xcalibur raw data files acquired on 
the LTQ-Orbitrap XL were directly imported into 
Progenesis LCMS software (Waters Corp) for peak 
detection and alignment. Data were analysed using the 
Mascot search engine. Five replicates were analysed for 
each sample type (N = 5). Statistical analyses were 
performed using ANOVA and only fold-changes in 
proteins with a p-value less than 0.05 were considered 
significant. 
 
Ingenuity pathway analyses. Pathway and function 
analyses were generated using Ingenuity Pathway 
Analysis (IPA) (Ingenuity systems, 
http://www.ingenuity.com), which assists with 
proteomics data interpretation via grouping 
differentially expressed genes or proteins into known 
functions and pathways. Pathways with a z score>1.9 
were considered as significantly activated, and 
pathways with a z score<-1.9 were considered as 
significantly inhibited. 
 
Graphs and correlation analyses. All graphs were done 
in Microsoft Excel except for correlation graphs. 
Correlations between protein expression and patient 
survival were calculated using a survival analysis tool 
available online (kmplot.com) [16].  
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